Patents Assigned to Andrulis Pharmaceuticals
  • Treatment of cancer with thalidomide alone or in combination with other anti-cancer agents
    Patent number: 6140346
    Abstract: A method is provided for the treatment of neoplastic diseases in a mammal which comprises administering to said mammal a therapeutically effective amount of thalidomide. The method also uses a combination of thalidomide with other anti-neoplastic agents. Additionally, pharmaceutical compositions containing thalidomide and other anti-cancer agents are also provided.
    Type: Grant
    Filed: May 4, 1998
    Date of Patent: October 31, 2000
    Assignee: Andrulis Pharmaceuticals Corp.
    Inventors: Peter J. Andrulis, Jr., Murray W. Drulak
  • Treatment of melanomas with thalidomide alone or in combination with other anti-melanoma agents
    Patent number: 5731325
    Abstract: A method for treatment of malignant melanoma by administering an effective amount of thalidomide alone or in combination with other anti-melanoma drugs.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: March 24, 1998
    Assignee: Andrulis Pharmaceuticals Corp.
    Inventors: Peter J. Andrulis, Jr., Murray W. Drulak
  • Treatment of inflammatory and/or autoimmune dermatoses with thalidomide alone or in combination with other agents
    Patent number: 5654312
    Abstract: Methods of treatment for inflammatory and autoimmune dermatoses which comprises topical and/or systemic administration of a therapeutically-effective amount of thalidomide alone or in combination with other dermatological agents.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: August 5, 1997
    Assignee: Andrulis Pharmaceuticals
    Inventors: Peter J. Andrulis, Jr., Murray W. Drulak
  • Treatment of ischemia/reperfusion injury with thalidomide alone or in combination with other therapies
    Patent number: 5643915
    Abstract: In accordance with the present invention, a method is provided for treating reperfusion injury, ischemia and runaway inflammatory conditions with thalidomide alone or in combination with other drugs selected from the group consisting of nitrates, beta-adrenoceptor blocking agents, anti-platelet/thrombolytic drugs, drugs acting as the arachindonic acid cascade and calcium antagonists. Pharmaceutical compositions comprising thalidomide alone or in combination with other drugs are also provided.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: July 1, 1997
    Assignee: Andrulis Pharmaceuticals Corp.
    Inventors: Peter J. Andrulis, Jr., Murray W. Drulak
  • Method for treating neurocognitive disorders
    Patent number: 5434170
    Abstract: A method for treating a central nervous system or peripheral nervous system cholinergic deficit state in a mammalian organism in need of such treatment, said method comprising administering to said mammal an amount of thalidomide effective in the treatment of a cholinergic deficit state and for a time sufficient to achieve a suitable blood level to treat said cholinergic deficit state.
    Type: Grant
    Filed: December 23, 1993
    Date of Patent: July 18, 1995
    Assignee: Andrulis Pharmaceuticals Corp.
    Inventor: Peter J. Andrulis, Jr.
  • Treatment of insulin resistant diabetes with thalidomine
    Patent number: 5405855
    Abstract: A method for treating insulin-resistant diabetes in mammals which comprises administering to said afflicted animals a prophylactically or therapeutically effective amount of thalidomide.
    Type: Grant
    Filed: December 23, 1993
    Date of Patent: April 11, 1995
    Assignee: Andrulis Pharmaceuticals Corp.
    Inventor: Peter J. Andrulis, Jr.